

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [editorial.bmjopen@bmj.com](mailto:editorial.bmjopen@bmj.com)

# BMJ Open

## The Efficacy of the Proprioceptive Neuromuscular Facilitation (PNF) approach in stroke rehabilitation to improve basic activities of daily living and quality of life: a systematic review and meta-analysis protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-016739
Article Type:	Protocol
Date Submitted by the Author:	07-Mar-2017
Complete List of Authors:	Guiu-Tula, Francesc; Blanquerna School of Health Science, Ramon Llull University, Physiotherapy Cabanas-Valdés, Rosa; Faculty of Medicine and Health Sciences, Universitat Internacional de Catalunya (UIC) , Physiotherapy Sitja-Rabert, Mercè; School of Health Science, Ramon Llull University, Physiotherapy Urrutia, Gerard; Centro Cochrane Iberoamericano; Institut d'Investigació Biomèdica Sant Pau, CIBERESP Gomara-Toldrà, Natalia; School of Health Science, Ramon Llull University, Physiotherapy
<b>Primary Subject Heading</b>:	Rehabilitation medicine
Secondary Subject Heading:	Neurology, Rehabilitation medicine
Keywords:	Proprioceptive neuromuscular facilitation, PNF, Kabat, Activities of daily living, Quality of life, Stroke < NEUROLOGY

SCHOLARONE™  
Manuscripts

1  
2  
3 **The Efficacy of the Proprioceptive Neuromuscular Facilitation (PNF) approach in**  
4 **stroke rehabilitation to improve basic activities of daily living and quality of life: a**  
5 **systematic review and meta-analysis protocol**  
6  
7

8  
9 Francesc Xavier Guiu-Tula<sup>a</sup>, Rosa Cabanas-Valdés<sup>b</sup>, Mercè Sitja-Rabert<sup>a</sup>, Gerard  
10 Urrutia<sup>c</sup>, Natalia Gomara-Toldrà<sup>a</sup>  
11

12  
13 <sup>a</sup>Blanquerna School of Health Science, Ramon Llull University, Physiotherapy,  
14 Barcelona, Catalonia, Spain  
15

16  
17 <sup>b</sup>Faculty of Medicine and Health Sciences, Universitat Internacional de Catalunya  
18 (UIC), Physiotherapy, Barcelona, Catalonia, Spain,  
19

20  
21 <sup>c</sup>Centro Cochrane Iberoamericano, Institut d'Investigació Biomèdica Sant Pau,  
22 CIBERESP, Barcelona, Catalonia, Spain  
23  
24

25  
26  
27  
28 Corresponding author:  
29

30  
31 [rosacabanas@uic.es](mailto:rosacabanas@uic.es) Rosa Cabanas-Valdés  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9

## The Efficacy of the Proprioceptive Neuromuscular Facilitation (PNF) approach in stroke rehabilitation to improve basic activities of daily living and quality of life: a systematic review and meta-analysis protocol

10  
11

### ABSTRACT

12  
13  
14  
15  
16  
17  
18  
19  
20  
21

**Introduction:** Proprioceptive neuromuscular facilitation (PNF) is an integrated approach although its efficacy has not yet been demonstrated in stroke survivors. The aim of this systematic review is to identify, assess and synthesize the potential benefits of PNF to improve the activities of daily living (ADL) and quality of life (QoL) in individuals with stroke.

22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

**Methods and analysis:** A systematic hand search will be conducted in Medline, Embase, CENTRAL and PEDro. We will include randomized controlled trials or quasi-randomized of PNF intervention in stroke survivors until March 2016. Two review authors will independently select relevant studies and will extract data using the recommendations of the Cochrane Handbook for systematic reviews of interventions and the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P). We will describe the results and conclusions of the included studies using the PEDro scale. If numeric data permit, we will carry out a meta-analysis.

36  
37  
38  
39  
40  
41  
42  
43

**Ethics and dissemination:** No ethical consideration will be required. Results will be disseminating in a peer-review journal. This systematic review aims to examine the effects of PNF (neurophysiological approach) to clarify its efficacy to improve the ADL and QoL on the rehabilitation of stroke survivors.

44  
45

**Trial registration number:** Prospero CRD42016039135

46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Keywords:** Stroke, Proprioceptive neuromuscular facilitation, PNF, Kabat, Activities of daily living, Quality of life, Physiotherapy.

### Strengths and limitations of this study

- To our knowledge this study is the first systematic review focalized in the proprioceptive neuromuscular facilitation (PNF) approach on stoke survivors.
- This systematic review has an open eligibility criteria's to clarify the efficacy of PNF method in different clinical situations for stroke patients.
- The electronic search was had language restriction to English, Spanish, Portuguese and French that could be limit the inclusion of studies.

## INTRODUCTION

Stroke was the second most common cause of death worldwide in 2010 and the third cause of disability-adjusted life-years.<sup>1-3</sup>

Stroke survivors have dramatically reduced their activities of daily living (ADL)<sup>4</sup> and their quality of life (QoL) is significantly lower than general population.<sup>5</sup> 50% of individuals with stroke require support in their ADL<sup>6</sup> specially those related to basic self-maintenance task (domestic and community).<sup>7</sup> Further, some of these difficulties are related to motor functions impairments.<sup>4</sup> Moreover, the functionality is closely linked with QoL.<sup>8</sup> The conceptualization of QoL is a challenging endeavor and is being used in different ways, however only “satisfaction with life” is correct QoL conceptualization.<sup>9</sup> The principal factors that affect the QoL are related to functional status and disability, among others.<sup>10</sup>

Considering these aspects, it is important to focus stroke rehabilitation on the functional recovery related to movement considering that functional movement is the ability to produce and maintain balance between mobility and stability.<sup>11</sup> This proper coordination requires an effective proprioceptive communication between the muscles and joints. In order to improve the neuromuscular system’s effectiveness in coordinating movement, there are different physiotherapy approaches amongst which is the proprioceptive neuromuscular facilitation (PNF).<sup>12</sup>

PNF approach exist since the late 1930s and '40s when a physician and neurologist named Herman Kabat and a physiotherapist Margaret Knott began using proprioceptive techniques on younger individuals with cerebral palsy and other neurological conditions. The main goal of this intervention method is to help patients to achieve their highest function level. PNF uses the body’s proprioceptive system to facilitate or inhibit muscle contraction. The definition of PNF involves proprioceptive (having to do with any of the sensory receptors that give information concerning movement and position of the body); neuromuscular (involving the nerves and muscles) and facilitation (making easier).<sup>13</sup>

Recently, various systematic reviews have evaluated the efficacy of stroke rehabilitation interventions, including PNF<sup>14-19</sup> and a guideline.<sup>20</sup> However, none of them was specifically focused in PNF. Only a narrative review assessed PNF as the principal

1  
2  
3 topic.<sup>21</sup> Further, the most frequent objectives to assess the efficacy of this intervention  
4 method was motor function and mobility. In conclusion, no prior systematic reviews  
5 assessing the relationship between ADL and QoL were identified.  
6  
7  
8 Eventually, it is necessary that therapist base their clinical decisions on the most reliable  
9 scientific evidence available.  
10

## 11 12 13 **OBJECTIVES**

14  
15  
16 The purpose of this systematic review is: to examine the efficacy of proprioceptive  
17 neuromuscular facilitation (PNF) to improve the ADL and the QoL in individuals with  
18 stroke. Secondary specific aims are to determine the efficacy of the PNF in postural  
19 control, gait, upper limb function and in muscle strength.  
20  
21  
22

## 23 24 **METHODS:**

25  
26  
27 This systematic review protocol was registered prospectively in Prospero (registration  
28 number: CRD42016039135) and will follow the recommendations of the Cochrane  
29 Handbook for systematic reviews of interventions<sup>22</sup> and will be reported in accordance  
30 with the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols  
31 (PRISMA-P).<sup>23</sup>  
32  
33  
34

### 35 36 37 **Criteria for considering studies for this review**

#### 38 39 *Type of studies*

40 We will include all randomized controlled trials and quasi-randomized controlled trials.  
41  
42  
43

#### 44 45 *Type of participants*

46 We will include adult stroke participants (>18 years old) in the acute, subacute or  
47 chronic phase.  
48  
49

#### 50 51 *Type of interventions*

52 We will include all trials which reported Proprioceptive Neuromuscular Facilitation  
53 (PNF) approach alone or in combination with another rehabilitation or medical  
54 intervention compared with a control group (conventional physiotherapy, another  
55 physiotherapy approach, no PNF, no treatment).  
56  
57  
58  
59  
60

### *Type of outcomes measures*

#### Primary outcomes:

- i) Activities of daily living (ADL) evaluated mainly by Barthel Index (BI), Functional Independence Measures (FIM), modified Ranking Scale (mRS), Community Integration Questionnaire (CIQ).
- ii) Quality of life (QoL) evaluated mainly by Medical Outcomes Study Short Form 36 (SF-36), Stroke Specific Quality of Life Scale (SS-QOL).

#### Secondary outcomes:

- i) Postural control assessed mainly by Postural Assessment Scale for Stroke Patients (PASS) and Rivermead Mobility Index (RMI), Trunk Impairment Scale (TIS).
- ii) Gait assessed mainly by Brunel Balance Assessment (BBA), Tinetti test, Functional Ambulation Category (FAC), Dynamic Gait Index (DGI), 6 Minute Walk Test (6MWT) or 10 Meter Walk Test (10MWT).
- iii) Upper limb function assessed mainly by Wolf Motor Function (WMFT), Fugl-Meyer Assessment (FMA), Box and Block Test (BBT) or Motor Activity Log (MAL).
- iv) Muscle strength assessed mainly by Oxford Scale, Hand-held Dynamometer/Grip Strength or Five Times Sit to Stand Test (FTSST).

#### **Search methods for identification of studies**

A systematic electronic search will be conducted in the following databases: The Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, 2016, Issue 3), MEDLINE (1964 to March 2016; via PubMed), EMBASE (1980 to March 2016; via Ovid) and PEDro (1999 to March 2016; via website). In addition, expert opinions' and the referent list of the selected studies and previous systematic reviews will be checked. Search strategy will involve two kinds of terms: "stroke" and "PNF" that will be combined with the Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE: sensitivity-maximizing version (2008 revision); PubMed format. Finally, language restrictions will be applied, only considering studies published in English, French, Spanish and Portuguese. This search



strategy is described in table 1.

**Table 1 Medline (PubMed) search strategy**

	1. "Cerebrovascular Disorders"[Mesh] OR stroke*[tiab] OR poststroke*[tiab] OR cerebral vascular OR accident*[tiab] OR cva*[tiab] OR brain injur*[ti] OR apoplex*[tiab]
	2. "Brain"[Mesh] OR brain*[tiab] OR cerebr*[tiab] OR cerebell*[tiab] OR intracran*[tiab] OR intracerebral*[tiab] OR vertebrobasilar*[tiab]
	3. "Blood vessels"[Mesh] OR blood vessel*[tiab] OR vascular*[tiab] OR "arteries"[Mesh] OR arter*[tiab]
	4. "Intracranial Aneurysm"[Mesh] OR "Intracranial Hemorrhages"[Mesh] OR "Intracranial OR Hemorrhage, Hypertensive"[Mesh] OR "Hematoma, Subdural, Intracranial"[Mesh] OR "Subarachnoid Hemorrhage"[Mesh] OR "SAH"[tiab]
	5. "Hemorrhage"[Mesh] OR hemorrhag*[tiab] OR haemorrhag*[tiab] OR "hematoma"[Mesh] OR hematoma*[tiab] OR haematoma*[tiab] OR bleed*[tiab]
<b>Stroke</b>	6. "Intracranial Embolism and Thrombosis"[Mesh] OR "Intracranial Embolism"[Mesh] OR "Vasospasm, OR Intracranial"[Mesh] OR "Ischemic Attack, Transient"[Mesh] OR "TIA"[tiab] OR "Brain Ischemia"[Mesh]
	7. "Ischemia"[Mesh] OR ischemi*[tiab] OR ischaemi*[tiab] OR thrombo*[tiab] OR "embolism"[Mesh] OR emboli*[tiab] OR oclus*[tiab]
	8. "Disease"[Mesh] OR disease*[tiab] OR disorder*[tiab] OR infarc*[tiab] OR stenosi*[tiab] OR spasm*[tiab] OR accident*[tiab]
	9. (#2 AND #7) OR #6
	10. (((#2 OR subarachnoid*[tiab]) AND #5) OR #4)
	11. #17 AND #23 AND #61
	12. #1 OR #9 OR #10 OR #11
	13. Neuromuscular facilitation*[tiab] OR neuromuscular stimulation*[tiab] OR proprioceptive*[ti] OR "PNF"[tiab] OR autogenic inhibition*[tiab] OR reciprocal inhibition*[tiab] OR rhythmic stabilization*[tiab] OR repeat contraction*[tiab] OR repeated contraction*[tiab] OR hold relax*[tiab] OR antagonist contract*[tiab] OR slow reversal*[tiab] OR functional stretch reflex*[tiab] OR reflex excitability*[tiab] OR contract relax*[tiab] OR "kabat"[tiab]
<b>Proprioceptive neuromuscular facilitation (PNF)</b>	
<b>Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE: sensitivity-maximizing versión (2008 revision); PubMed format</b>	14. Randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized [tiab] OR placebo [tiab] OR drug therapy [sh] OR randomly [tiab] OR trial [tiab] OR groups [tiab]
	15. Animals [mh] NOT humans [mh]
	16. #15 NOT #16
<b>Final Search</b>	17. #12 AND #13 AND #16

## Data collection and analysis

### *Study Selection*

Two review authors will independently screen all retrieved references and select studies that meet the selection criteria following these steps: (1) reading title and abstracts and then (2) by reading the full texts.

### *Data extraction and management*

Two reviewers independently will extract data using a data extraction form, which will be designed, and tested prior to use. Disagreements will be resolved by discussion or, if necessary, referred to a third author.

The data extraction form will be based on the recommendations of the Cochrane handbook for systematic reviews of interventions<sup>22</sup> and will extract information from each selected study on demographic characteristics (e.g. age, gender, time since stroke, side of the paresis, unilateral or bilateral stroke, first ever or the recurrent stroke the etiologic and the localization of stroke lesions), study design, description of intervention in the experimental and control groups, risk of bias, outcomes measures and results. For a better data reporting, we will use the TIDieR (Template for intervention description and replication)<sup>24</sup> in the intervention section and the PEDro scale<sup>25</sup> to assess the risk of bias.

### *Assessment of the risk of bias in individual studies*

Two review authors will independently evaluate the methodological quality from each selected study using the PEDro scale.<sup>25</sup> Disagreements will be resolved by involving a third author.

### *Measures of treatment effect*

This review will express results from continuous outcomes with the mean difference (if the same scale is available) or standardized mean difference (if different scales were used) with 95% confidence intervals, and dichotomous outcomes with risk differences and 95% confidence intervals.<sup>21</sup>

### *Data synthesis*

If a meta-analysis is possible, statistical analysis will be conducted by Revman 5.3. We will use fixed effects model to summarize the results of studies with non-significant heterogeneity; otherwise, we will use the random effects model. If there is great heterogeneity within the studies (I-squared >70%), which does not allow for a meta-analysis, a narrative synthesis of the available data will be conducted.<sup>22</sup>

### *Dealing with missing data*

If data are missing, if possible, we will contact with the original authors to request the missing data, especially those necessary for the completion of the meta-analysis.<sup>22</sup>

### *Assessment of heterogeneity*

Heterogeneity will be assessed using the I<sup>2</sup> statistic according to the recommendations of the Cochrane Handbook for Systematic Reviews of Interventions.<sup>21</sup> Values greater than 50% will indicate the existence of substantial heterogeneity.<sup>22</sup>

### *Subgroup analysis and investigation of heterogeneity*

We will consider the following subgroups: the etiology from the disease, type of stroke; stroke localization, stroke severity evaluated by the National institute of Health Stroke Scale (NIHSS) and modified Rankin Scale, thrombolysis and thrombectomy treatment, the chronicity of the disease. Finally, for the evaluation of the methodological heterogeneity will take in account the study design and the risk of bias of the studies included.<sup>22</sup>

### *Sensitivity analysis*

We will perform a sensitivity analysis as follows: (a) random allocation, (b) concealed allocation, (c) methodological quality, (d) subjects blinding, (e) therapists blinding, (f) outcomes assessor blinding, and (g) intention to treat analysis and (h) drop outs.<sup>22</sup>

## **DISCUSSION**

This systematic review will focus on the different techniques of Proprioceptive

1  
2  
3 Neuromuscular Facilitation (PNF) that are currently applied in stroke survivors to  
4 explore their influence in Activities of daily living (ADL) and Quality of life (QoL).  
5 PNF has been a very important part of therapeutic techniques for years. More recently,  
6 the focus on functional activities has allowed the techniques of PNF to become an  
7 integral part of this type of exercise programming. PNF can and should be incorporated  
8 into any functional training by stroke survivors.  
9  
10  
11  
12

### 13 FOOTNOTES

14 Acknowledgements: We would like to acknowledge the contribution of Blanquerna  
15 School of Science (Universitat Ramon Llull) and Iberoamerican Cochrane Center for  
16 their support to the first author.  
17  
18  
19  
20  
21

22 Contributor ship statement: MS and XG designed and drafted the initial part of this  
23 study protocol. After that, all authors did substantial contributions to the design of the  
24 work; the analysis, and the interpretation of data for the work; and drafting the work and  
25 revising it critically for important intellectual content; and final approval of the version  
26 to be published; and all authors agreement to be accountable for all aspects of the work  
27 in ensuring that questions related to the accuracy or integrity of any part of the work are  
28 appropriately investigated and resolved.  
29  
30  
31  
32  
33  
34

35 Funding: This paper will be support by the College of Physiotherapists of Catalonia.  
36 Identification number: 43981/2015.  
37  
38  
39

40 Competing interest: The authors declare they have no competing interests.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

1. Feigin VL, Forouzanfar MH, Krishnamurthi R, et al. Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. *Lancet* 2014;383(9913):245.
2. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012;380(9859):2095. doi: 10.1016/s0140-6736(12)61728-0
3. Murray CJL, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012;380(9859):2197. doi: 10.1016/s0140-6736(12)61689-4
4. Fujita T, Sato A, Togashi Y, et al. Identification of the affected lower limb and unaffected side motor functions as determinants of activities of daily living performance in stroke patients using partial correlation analysis. *Journal of Physical Therapy Science* 2015;27(7):2217. doi: 10.1589/jpts.27.2217
5. Laurent K, De Sèze MP, Delleci C, et al. Assessment of quality of life in stroke patients with hemiplegia. *Ann Phys Rehabil Med* 2011;54(6):376. doi: 10.1016/j.rehab.2011.06.002
6. White JH, Alston MK, Marquez JL, et al. Community-dwelling stroke survivors: function is not the whole story with quality of life. *Archives of Physical Medicine and Rehabilitation* 2007;88(9):1140. doi: 10.1016/j.apmr.2007.06.003
7. Stroke Foundation of New Z, New Zealand Guidelines G. New Zealand clinical guidelines for stroke management 2010. Wellington, N.Z.: Stroke Foundation of New Zealand 2011.
8. Fryer CE, Luker JA, McDonnell MN, et al. Self management programmes for quality of life in people with stroke. *Cochrane Database Syst Rev* 2016(8) doi: 10.1002/14651858.CD010442.pub2
9. Dijkers M. "What's in a name?" The indiscriminate use of the "Quality of life" label, and the need to b s2005.07.003
11. Nesser TW, Huxel KC, Tincher JL, et al. The relationship between core stability and performance in division I football players. *J Strength Cond Res* 2008;22(6):1750. doi: 10.1519/JSC.0b013e3181874564

12. Voss DE, Ionta MK, Myers BJ, et al. Proprioceptive neuromuscular facilitation: patterns and techniques. 3rd ed ed. Philadelphia: Harper & Row 1985.
13. Adler SS, Beckers D, Buck M. PNF in Practice. Berlin, Heidelberg: Springer Berlin Heidelberg 2014.
14. Almeida PMD, Santo A, Dias B, et al. Hands-on physiotherapy interventions and stroke and International Classification of Functionality, Disability and Health outcomes: A systematic review. *European Journal of Physiotherapy* 2015;17(3):100. doi: 10.3109/21679169.2015.1044466
15. Pollock A, Baer G, Campbell P, et al. Physical rehabilitation approaches for the recovery of function and mobility following stroke. *Cochrane Database Syst Rev* 2014(4) doi: 10.1002/14651858.CD001920.pub3
16. Veerbeek JM, van Wegen E, van Peppen R, et al. What is the evidence for physical therapy poststroke? A systematic review and meta-analysis. *PloS One* 2014;9(2) doi: 10.1371/journal.pone.0087987
17. Winter J, Hunter S, Sim J, et al. Hands-on therapy interventions for upper limb motor dysfunction following stroke. *Cochrane Database Syst Rev* 2011(6) doi: 10.1002/14651858.CD006609.pub2
18. Pollock A, Baer G, Pomeroy V, et al. Physiotherapy treatment approaches for the recovery of postural control and lower limb function following stroke. *Cochrane Database Syst Rev* 2007(1) doi: 10.1002/14651858.CD001920.pub2
19. Van Peppen RP, Kwakkel G, Wood-Dauphinee S, et al. The impact of physical therapy on functional outcomes after stroke: what's the evidence? *Clin Rehabil* 2004;18(8):833-62. [published Online First: 2004/12/22]
20. Ottawa P, Khadilkar A, Phillips K, et al. Ottawa panel evidence-based clinical practice guidelines for post-stroke rehabilitation. *Topics in Stroke Rehabilitation* 2006;13(2):1. doi: 10.1310/3tkx-7xec-2dtg-xqkh
21. Smedes F, Heidmann M, Schäfer C, et al. The proprioceptive neuromuscular facilitation-concept; the state of the evidence, a narrative review. *Physical Therapy Reviews* 2016;21(1):17. doi: 10.1080/10833196.2016.1216764
22. Cochrane handbook for systematic reviews of interventions. Chichester, England ; Hoboken, NJ: Wiley-Blackwell 2011.
23. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4 doi: 10.1186/2046-4053-4-1

1  
2  
3 24. Hoffmann TC, Glasziou PP, Boutron I, et al. Better reporting of interventions:  
4 template for intervention description and replication (TIDieR) checklist and guide. *Bmj*  
5 2014;348  
6  
7

8 25. Maher CG, Sherrington C, Herbert RD, et al. Reliability of the PEDro scale for  
9 rating quality of randomized controlled trials. *Physical Therapy* 2003;83(8):713.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



# PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
<b>TITLE</b>			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
<b>ABSTRACT</b>			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	5
<b>METHODS</b>			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	5
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	6
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	7
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	8
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	8
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	6
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	8
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	9
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., $I^2$ for each meta-analysis <a href="http://bmjopen.bmj.com/site/about/guidelines.xhtml">http://bmjopen.bmj.com/site/about/guidelines.xhtml</a> ).	9





# PRISMA 2009 Checklist

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	9
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	9
<b>RESULTS</b>			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	No
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	No
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	No
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	No
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	No
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	No
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	No
<b>DISCUSSION</b>			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	10
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	10
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	10
<b>FUNDING</b>			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	10

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: [www.prisma-statement.org](http://www.prisma-statement.org).

# BMJ Open

## The Efficacy of the Proprioceptive Neuromuscular Facilitation (PNF) approach in stroke rehabilitation to improve basic activities of daily living and quality of life: a systematic review and meta-analysis protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-016739.R1
Article Type:	Protocol
Date Submitted by the Author:	09-Jun-2017
Complete List of Authors:	Guiu-Tula, Francesc; Blanquerna School of Health Science, Ramon Llull University, Physiotherapy Cabanas-Valdés, Rosa; Faculty of Medicine and Health Sciences, Universitat Internacional de Catalunya (UIC) , Physiotherapy Sitja-Rabert, Mercè; Blanquerna School of Health Science, Ramon Llull University, Physiotherapy Urrutia, Gerard; Centro Cochrane Iberoamericano; Institut d'Investigació Biomèdica Sant Pau, CIBERESP Gomara-Toldrà, Natalia; Blanquerna School of Health Science, Ramon Llull University, Physiotherapy
<b>Primary Subject Heading</b>:	Rehabilitation medicine
Secondary Subject Heading:	Neurology
Keywords:	Proprioceptive neuromuscular facilitation, PNF, Kabat, Activities of daily living, Quality of life, Stroke < NEUROLOGY

SCHOLARONE™  
Manuscripts

1  
2  
3 **The Efficacy of the Proprioceptive Neuromuscular Facilitation (PNF) approach in**  
4 **stroke rehabilitation to improve basic activities of daily living and quality of life: a**  
5 **systematic review and meta-analysis protocol**  
6  
7

8  
9 Francesc Xavier Guiu-Tula<sup>a</sup>, Rosa Cabanas-Valdés<sup>b</sup>, Mercè Sitjà-Rabert<sup>a</sup>, Gerard  
10 Urrútia<sup>c</sup>, Natàlia Gómara-Toldrà<sup>a</sup>  
11

12  
13 <sup>a</sup>Blanquerna School of Health Science, Ramon Llull University, Physiotherapy,  
14 Barcelona, Catalonia, Spain  
15

16  
17 <sup>b</sup>Faculty of Medicine and Health Sciences, Universitat Internacional de Catalunya  
18 (UIC), Physiotherapy, Barcelona, Catalonia, Spain,  
19

20  
21 <sup>c</sup>Centro Cochrane Iberoamericano, Institut d'Investigació Biomèdica Sant Pau,  
22 CIBERESP, Barcelona, Catalonia, Spain  
23  
24

25  
26  
27  
28 Corresponding author:  
29

30  
31 [rosacabanas@uic.es](mailto:rosacabanas@uic.es) Rosa Cabanas-Valdés  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9

## The Efficacy of the Proprioceptive Neuromuscular Facilitation (PNF) approach in stroke rehabilitation to improve basic activities of daily living and quality of life: a systematic review and meta-analysis protocol

10  
11

### ABSTRACT

12  
13  
14  
15  
16  
17  
18  
19  
20  
21

**Introduction:** Proprioceptive neuromuscular facilitation (PNF) is a widely used rehabilitation concept although its efficacy has not yet been demonstrated in stroke survivors. The aim of this systematic review is to identify, assess and synthesize the potential benefits of PNF to improve the activities of daily living (ADL) and quality of life (QoL) in individuals with stroke.

22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

**Methods and analysis:** A systematic electronic search will be conducted in Medline, Embase, CENTRAL and PEDro. We will include randomized controlled trials or quasi-randomized of PNF interventions in stroke survivors until April 2017. Two reviewers authors will independently select relevant studies and will extract data using the approach of the Cochrane Handbook for systematic reviews of interventions and the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P). The methodological quality will be assessed by using the PEDro scale. Finally, the numeric data permitting, we will carry out a meta-analysis.

36  
37  
38  
39  
40  
41  
42  
43

**Ethics and dissemination:** No ethical considerations will be required. Results will be disseminated in a peer-review journal. This systematic review aims to examine the effects of PNF (neurophysiological approach) in order to clarify its efficacy to improve the ADL and QoL in the rehabilitation process of stroke survivors.

44  
45

**Trial registration number:** Prospero CRD42016039135

46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Keywords:** Stroke, Proprioceptive neuromuscular facilitation, PNF, Kabat, Activities of daily living, Quality of life, Physiotherapy.

### Strengths and limitations of this study

- To our knowledge this study is the first systematic review focused in the proprioceptive neuromuscular facilitation (PNF) approach for stroke survivors.
- This systematic review has an open eligibility criteria to clarify the efficacy of the PNF method for different clinical situations in stroke patients.
- The electronic search will only include randomized controlled trials published in English, Spanish, French and Portuguese that could limit the inclusion of studies.

## INTRODUCTION

Although age-standardized rates of stroke mortality have decreased worldwide in the past two decades, the total number of people who have a stroke every year, as well as stroke survivors, related deaths, and the overall global burden of stroke (DALYs lost) is increasing.<sup>1</sup>

Stroke survivors dramatically reduce their activities of daily living (ADL)<sup>2</sup> and their quality of life (QoL) is significantly lower than that of the general population.<sup>3</sup> 50% of individuals with stroke require support in their ADL<sup>4</sup> specially in those related to basic self-maintenance tasks (domestic and community).<sup>5</sup> Treatments are focused to recover maximal functions of stroke survivors at discharge, and hence may be an important factor to improve the functionality and QoL in stroke survivors.<sup>6</sup> The QoL construct has fluctuated over the years and at present has multiple conceptualizations, as a result, the clinical studies do not accurately define what QoL is and how it operates.<sup>7,8</sup> The current trend is that the conceptualization of QoL is classified over three different areas; QoL as a subjective well-being; QoL as achievements; and QoL as utility.<sup>8</sup> QoL as achievements refers to people's possessions, relationships and accomplishments, among others, using metrics defined by an outsider's point of view. In QoL as utility, achievements and statuses are judged in terms of societal norms and standards that quantify the value of a life.

Considering these aspects, it is important to focus stroke rehabilitation on the functional recovery related to movement considering that functional movement is the ability to produce and maintain balance between mobility and stability.<sup>9</sup> This proper coordination requires an effective proprioceptive communication between the muscles and joints. In order to improve the neuromuscular system's effectiveness in coordinating movement, there are different physiotherapy approaches amongst which is the proprioceptive neuromuscular facilitation (PNF).<sup>10</sup>

PNF approach has existed since the late 1930s and '40s when a physician and neurologist; Herman Kabat, and a physiotherapist; Margaret Knott, began using proprioceptive techniques on younger individuals with cerebral palsy and other neurological conditions. The main goal of this intervention method is to help patients to achieve their highest function level. PNF uses the body's proprioceptive system to

1  
2  
3 facilitate or inhibit muscle contraction. The definition of PNF involves proprioceptive  
4 (having to do with any of the sensory receptors that give information concerning  
5 movement and position of the body); neuromuscular (involving the nerves and muscles)  
6 and facilitation (making it easier).<sup>11</sup>  
7  
8

9  
10 Recently, various systematic reviews have evaluated the efficacy of stroke rehabilitation  
11 interventions, including PNF<sup>12-17</sup> and a guideline.<sup>18</sup> However, none were specifically  
12 focused on PNF, with only a narrative review assessing PNF as the principal topic.<sup>19</sup>  
13 Furthermore, the most frequent objectives to assess the efficacy of this intervention  
14 method was motor function and mobility. It is necessary that therapists base their  
15 clinical decisions on the most reliable scientific evidence available, hence this  
16 systematic review aims to determine the efficacy of PNF techniques to improve the  
17 ADL and QoL in stroke survivors, by determining the efficacy of PNF techniques.  
18  
19  
20  
21  
22  
23  
24

## 25 26 27 **OBJECTIVES**

28  
29 The purpose of this systematic review is: to examine the efficacy of proprioceptive  
30 neuromuscular facilitation (PNF) to improve the ADL and the QoL in individuals with  
31 stroke. Secondary specific aims are to determine the efficacy of the PNF techniques in  
32 postural control, gait, upper limb function and in muscle strength.  
33  
34  
35  
36

## 37 38 **METHODS:**

39  
40 This systematic review protocol was registered prospectively in Prospero (registration  
41 number: CRD42016039135) and will follow the recommendations of the Cochrane  
42 Handbook for systematic reviews of interventions<sup>20</sup> and will be reported in accordance  
43 with the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols  
44 (PRISMA-P).<sup>21</sup>  
45  
46  
47  
48

## 49 50 **Criteria for considering studies for this review**

### 51 52 *Type of studies*

53 We will include all randomized controlled trials and quasi-randomized controlled trials.  
54  
55

### 56 57 *Type of participants*

58  
59  
60

We will include adult stroke participants (>18 years old) in the acute, subacute or chronic phase.

#### *Type of interventions*

We will include all trials which reported Proprioceptive Neuromuscular Facilitation (PNF) approach alone or in combination with another rehabilitation or medical intervention compared with a control group (conventional physiotherapy, another physiotherapy approach, no PNF, no treatment).

#### *Type of outcomes measures*

##### Primary outcomes:

- i) Activities of daily living (ADL) evaluated mainly by Barthel Index (BI), Functional Independence Measures (FIM), modified Ranking Scale (mRS) and Community Integration Questionnaire (CIQ).
- ii) Quality of life (QoL) evaluated mainly by Medical Outcomes Study Short Form 36 (SF-36) and Stroke Specific Quality of Life Scale (SS-QOL).

##### Secondary outcomes:

- i) Postural control assessed mainly by Postural Assessment Scale for Stroke Patients (PASS), Rivermead Mobility Index (RMI) and the Trunk Impairment Scale (TIS).
- ii) Gait assessed mainly by Brunel Balance Assessment (BBA), Tinetti test, Functional Ambulation Category (FAC), Dynamic Gait Index (DGI), 6 Minute Walk Test (6 MWT) or 10 Meter Walk Test (10 MWT).
- iii) Upper limb function assessed mainly by Wolf Motor Function (WMFT), Fugl-Meyer Assessment (FMA), Box and Block Test (BBT) or Motor Activity Log (MAL).
- iv) Muscle strength assessed mainly by Oxford Scale, Hand-held Dynamometer/Grip Strength or Five Times Sit to Stand Test (FTSST).

#### **Search methods for identification of studies**

A systematic electronic search will be conducted in the following databases: The Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library,



2017, Issue 3), MEDLINE (1964 to April 2017; via PubMed), EMBASE (1980 to April 2017; via Ovid) and PEDro (1999 to April 2017; via website). In addition, expert opinions' and the referent list of the selected studies and previous systematic reviews will be reviewed. The Search strategy will involve two kinds of terms: "stroke" and "PNF" that will be combined with the Cochrane Highly Sensitive Search Strategy for the identification of randomized trials in MEDLINE: sensitivity-maximizing version (2008 revision); PubMed format. Finally, all studies published in English, Spanish, French, and Portuguese will be included. This search strategy is described in table 1.

**Table 1 Medline (PubMed) search strategy**

1	1. "Cerebrovascular Disorders"[Mesh] OR stroke*[tiab] OR poststroke*[tiab] OR
2	cerebral vascular OR accident*[tiab] OR cva*[tiab] OR brain injur*[ti] OR
3	apoplex*[tiab]
4	2. "Brain"[Mesh] OR brain*[tiab] OR cerebr*[tiab] OR cerebell*[tiab] OR
5	intracran*[tiab] OR intracerebral*[tiab] OR vertebrobasilar*[tiab]
6	3. "Blood vessels"[Mesh] OR blood vessel*[tiab] OR vascular*[tiab] OR
7	"arteries"[Mesh] OR arter*[tiab]
8	4. "Intracranial Aneurysm"[Mesh] OR "Intracranial Hemorrhages"[Mesh] OR
9	"Intracranial OR Hemorrhage, Hypertensive"[Mesh] OR "Hematoma,
10	Subdural, Intracranial"[Mesh] OR "Subarachnoid Hemorrhage"[Mesh] OR
11	"SAH"[tiab]
12	5. "Hemorrhage"[Mesh] OR hemorrhag*[tiab] OR haemorrhag*[tiab] OR
13	"hematoma"[Mesh] OR hematoma*[tiab] OR haematoma*[tiab] OR
14	bleed*[tiab]
15	6. "Intracranial Embolism and Thrombosis"[Mesh] OR "Intracranial
16	Embolism"[Mesh] OR "Vasospasm, OR Intracranial"[Mesh] OR "Ischemic
17	Attack, Transient"[Mesh] OR "TIA"[tiab] OR "Brain Ischemia"[Mesh]
18	7. "Ischemia"[Mesh] OR ischemi*[tiab] OR ischaemi*[tiab] OR thrombo*[tiab]
19	OR "embolism"[Mesh] OR emboli*[tiab] OR oclus*[tiab]
20	8. "Disease"[Mesh] OR disease*[tiab] OR disorder*[tiab] OR infarc*[tiab] OR
21	stenosi*[tiab] OR spasm*[tiab] OR accident*[tiab]
22	9. (#2 AND #7) OR #6
23	10. (((#2 OR subarachnoid*[tiab]) AND #5) OR #4)
24	11. #17 AND #23 AND #61
25	12. #1 OR #9 OR #10 OR #11
26	13. Neuromuscular facilitation*[tiab] OR neuromuscular stimulation*[tiab] OR
27	proprioceptive*[ti] OR "PNF"[tiab] OR autogenic inhibition*[tiab] OR
28	reciprocal inhibition*[tiab] OR rhythmic stabilization*[tiab] OR repeat
29	contraction*[tiab] OR repeated contraction*[tiab] OR hold relax*[tiab] OR
30	antagonist contract*[tiab] OR slow reversal*[tiab] OR functional stretch
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	

reflex\*[tiab] OR reflex excitability\*[tiab] OR contract relax\*[tiab] OR "kabat"[tiab]

<p><b>Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE: sensitivity-maximizing versión (2008 revision); PubMed format</b></p>	<p>14. Randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized [tiab] OR placebo [tiab] OR drug therapy [sh] OR randomly [tiab] OR trial [tiab] OR groups [tiab]</p> <p>15. Animals [mh] NOT humans [mh]</p> <p>16. #15 NOT #16</p>
<p><b>Final Search</b></p>	<p>17. #12 AND #13 AND #16</p>

---

## Data collection and analysis

### *Study Selection*

Two reviewers will independently screen all retrieved references and select studies that meet the inclusion criteria following these steps: (1) reading title and abstracts and then (2) by reading the full-texts.

### *Data extraction and management*

Two reviewers independently will extract data using a data extraction form, which will be designed, and tested prior to use. Disparities will be resolved by discussion or, if necessary, referred to a third reviewer.

The data extraction form will be based on the recommendations of the Cochrane handbook for systematic reviews of interventions<sup>20</sup> and will extract information from each selected study on demographic characteristics (e.g. age, gender, time since stroke, side of the paresis, unilateral or bilateral stroke, first ever or the recurrent stroke the etiologic and the localization of stroke lesions), study design, description of intervention conducted both in the experimental and control groups, risk of bias, outcomes measures and results. For better data reporting, we will use the TIDieR (Template for intervention description and replication)<sup>22</sup> in the intervention section and the PEDro scale<sup>23</sup> to assess the risk of bias.

### *Assessment of the risk of bias in individual studies*

Two reviewers will independently evaluate the methodological quality from each selected study using the PEDro scale.<sup>23</sup> Disparities will be resolved by involving a third author.

### *Measures of treatment effect*

Within this systematic review, results from continuous outcomes will be reported with the mean difference (if the same scale is available) or standardized mean difference (if different scales were used) with 95% confidence intervals, and dichotomous outcomes with risk differences and 95% confidence intervals.<sup>19</sup>

### *Data synthesis*

If a meta-analysis is possible, statistical analysis will be conducted by Revman 5.3. We will use a fixed effects model to summarize the results of the studies with non-significant heterogeneity; otherwise, we will use the random effects model. If there is great heterogeneity within the studies (I-squared >70%), which does not allow the performance of a meta-analysis, a narrative synthesis of the available data will be conducted.<sup>20</sup>

### *Dealing with missing data*

If data is unreported, when possible, we will contact the original authors to request the missing data, especially for those necessary for the completion of the meta-analysis.<sup>20</sup>

### *Assessment of heterogeneity*

Heterogeneity will be assessed using the I<sup>2</sup> statistic according to the recommendations of the Cochrane Handbook for Systematic Reviews of Interventions<sup>20</sup> Values greater than 50% will indicate the existence of substantial heterogeneity.<sup>20</sup>

### *Subgroup analysis and investigation of heterogeneity*

We will consider the following variables: the etiology of the disease, type of stroke; stroke localization, stroke severity evaluated by the National Institute of Health Stroke Scale (NIHSS) and modified Rankin Scale, thrombolysis and thrombectomy treatment,

1  
2  
3 and the chronicity of the disease. Finally, for the evaluation of the methodological  
4 heterogeneity, will take the study design and the risk of bias of the studies included into  
5 account.<sup>20</sup>  
6  
7

### 8 9 *Sensitivity analysis*

10  
11 We will perform a sensitivity analysis as follows: (a) random allocation, (b) concealed  
12 allocation, (c) methodological quality, (d) subjects blinding, (e) therapists blinding, (f)  
13 outcomes assessor blinding, and (g) intention to treat analysis and (h) drop outs.<sup>20</sup>  
14  
15  
16

## 17 18 **DISCUSSION**

19  
20 This systematic review will focus on the different techniques of Proprioceptive  
21 Neuromuscular Facilitation (PNF) that are currently applied in stroke survivors to  
22 explore their influence in Activities of daily living (ADL) and Quality of life (QoL).  
23 PNF has been a very important part of the therapeutic techniques for years. More  
24 recently, the focus on functional activities has allowed the techniques of PNF to become  
25 an integral part of this type of exercise programming. PNF can and should be  
26 incorporated into any functional training by stroke survivors.  
27  
28  
29  
30  
31  
32  
33

## 34 35 **FOOTNOTES**

36  
37 Acknowledgements: We would like to acknowledge the contribution of Blanquerna  
38 School of Health Science (Ramon Llull University) and Iberoamerican Cochrane Center  
39 to serve their installations and services to the first author. We would like to  
40 acknowledge the contribution of Montse León (ML) and Gary Gibson (GG) for his  
41 assistance and help in the editing process of the manuscript.  
42  
43  
44  
45  
46

47 Contributorship statement: Francesc Xavier Guiu-Tula (FXGT) conceived, designed  
48 and co-ordinated the protocol review. He registered the protocol review in the Prospero  
49 database, wrote the protocol review, provided a clinical perspective and commented on  
50 drafts of the protocol review, and contributed to and approved the final manuscript of  
51 the protocol review. Rosa Cabanas-Valdés (RCV) provided a clinical perspective,  
52 especially to the PNF method. She contributes to the outcome assessment and  
53 commented on drafts of the protocol review, and contributed to and approved the final  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 manuscript of the protocol review. Mercè Sitjà-Rabert (MSR) conceived and designed  
4 the review. She provided a methodological perspective and she wrote the manuscript  
5 and commented on drafts of the protocol review, and contributed to and approved the  
6 final manuscript of the protocol review. Gerard Urrútia (GU) provided a methodological  
7 perspective, commented on drafts of the protocol review, and contributed to and  
8 approved the final manuscript of the protocol review. Natàlia Gómara-Toldrà (NGT)  
9 provided a clinical perspective, especially to the assessment outcomes and quality of life  
10 construct. She wrote the manuscript and commented on drafts of the protocol review,  
11 and contributed to and approved the final manuscript of the protocol review.  
12  
13  
14  
15  
16  
17  
18  
19

20 Funding: This paper will be supported by the College of Physiotherapists of Catalonia.  
21 Scholarship granted to Natàlia Gómara-Toldrà. Identification number: 43981/2015 and  
22 by the Iberoamerican Cochrane Center.  
23  
24  
25

26 Competing interest: The authors declare not to have any competing interests.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

1. Feigin VL, Forouzanfar MH, Krishnamurthi R, et al. Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. *Lancet (London, England)* 2014;383:245-54.
2. Fujita T, Sato A, Togashi Y, et al. Identification of the affected lower limb and unaffected side motor functions as determinants of activities of daily living performance in stroke patients using partial correlation analysis. *Journal of Physical Therapy Science* 2015;27(7):2217. doi: 10.1589/jpts.27.2217
3. Laurent K, De Sèze MP, Delleci C, et al. Assessment of quality of life in stroke patients with hemiplegia. *Ann Phys Rehabil Med* 2011;54(6):376. doi: 10.1016/j.rehab.2011.06.002
4. White JH, Alston MK, Marquez JL, et al. Community-dwelling stroke survivors: function is not the whole story with quality of life. *Archives of Physical Medicine and Rehabilitation* 2007;88(9):1140. doi: 10.1016/j.apmr.2007.06.003
5. Stroke Foundation of New Z, New Zealand Guidelines G. New Zealand clinical guidelines for stroke management 2010. Wellington, N.Z.: Stroke Foundation of New Zealand 2011.
6. Chang WH, Sohn MK, Lee J, et al. Predictors of functional level and quality of life at 6 months after a first-ever stroke: the KOSCO study. *Journal of Neurology* 2016;263:1166-77. doi: 10.1007/s00415-016-8119-y
7. Dijkers M. "What's in a name?" The indiscriminate use of the "Quality of life" label, and the need to bring about clarity in conceptualizations. *International Journal of Nursing Studies* 2007;44:153-55. doi: 10.1016/j.ijnurstu.2006.07.016
8. Dijkers MPJM. Quality of life of individuals with spinal cord injury: a review of conceptualization, measurement, and research findings. *Journal of Rehabilitation Research and Development* 2005;42:87-110.
9. Nesser TW, Huxel KC, Tincher JL, et al. The relationship between core stability and performance in division I football players. *J Strength Cond Res* 2008;22(6):1750. doi: 10.1519/JSC.0b013e3181874564
10. Voss DE, Ionta MK, Myers BJ, et al. Proprioceptive neuromuscular facilitation: patterns and techniques. 3rd ed ed. Philadelphia: Harper & Row 1985.
11. Adler SS, Beckers D, Buck M. PNF in Practice. Berlin, Heidelberg: Springer Berlin Heidelberg 2014.
12. Almeida PMD, Santo A, Dias B, et al. Hands-on physiotherapy interventions and stroke and International Classification of Functionality, Disability and Health outcomes: A systematic review. *European Journal of Physiotherapy* 2015;17(3):100. doi: 10.3109/21679169.2015.1044466
13. Pollock A, Baer G, Campbell P, et al. Physical rehabilitation approaches for the recovery of function and mobility following stroke. *Cochrane Database Syst Rev* 2014(4) doi: 10.1002/14651858.CD001920.pub3
14. Veerbeek JM, van Wegen E, van Peppen R, et al. What is the evidence for physical therapy poststroke? A systematic review and meta-analysis. *PloS One* 2014;9(2) doi: 10.1371/journal.pone.0087987
15. Winter J, Hunter S, Sim J, et al. Hands-on therapy interventions for upper limb motor dysfunction following stroke. *Cochrane Database Syst Rev* 2011(6) doi: 10.1002/14651858.CD006609.pub2

16. Pollock A, Baer G, Pomeroy V, et al. Physiotherapy treatment approaches for the recovery of postural control and lower limb function following stroke. *Cochrane Database Syst Rev* 2007(1) doi: 10.1002/14651858.CD001920.pub2
17. Van Peppen RP, Kwakkel G, Wood-Dauphinee S, et al. The impact of physical therapy on functional outcomes after stroke: what's the evidence? *Clin Rehabil* 2004;18(8):833-62. [published Online First: 2004/12/22]
18. Ottawa P, Khadilkar A, Phillips K, et al. Ottawa panel evidence-based clinical practice guidelines for post-stroke rehabilitation. *Topics in Stroke Rehabilitation* 2006;13(2):1. doi: 10.1310/3tkx-7xec-2dtg-xqkh
19. Smedes F, Heidmann M, Schäfer C, et al. The proprioceptive neuromuscular facilitation-concept; the state of the evidence, a narrative review. *Physical Therapy Reviews* 2016;21(1):17. doi: 10.1080/10833196.2016.1216764
20. Cochrane handbook for systematic reviews of interventions. Chichester, England ; Hoboken, NJ: Wiley-Blackwell 2011.
21. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4 doi: 10.1186/2046-4053-4-1
22. Hoffmann TC, Glasziou PP, Boutron I, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. *Bmj* 2014;348
23. Maher CG, Sherrington C, Herbert RD, et al. Reliability of the PEDro scale for rating quality of randomized controlled trials. *Physical Therapy* 2003;83(8):713.

review only



# PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
<b>TITLE</b>			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
<b>ABSTRACT</b>			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	5
<b>METHODS</b>			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	5
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	6
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	7
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	8
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	8
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	6
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	9
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	9
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I <sup>2</sup> for each meta-analysis).	10





# PRISMA 2009 Checklist

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

BMJ Open: first published as 10.1136/bmjopen-2017-016739 on 12 December 2017. Downloaded from <http://bmjopen.bmj.com/> on April 29, 2024 by guest. Protected by copyright.

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	9
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	9
<b>RESULTS</b>			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	No
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	No
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	No
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	No
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measure of consistency.	No
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	No
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	No
<b>DISCUSSION</b>			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	10
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	3
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	10
<b>FUNDING</b>			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	11

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: [www.prisma-statement.org](http://www.prisma-statement.org).

# BMJ Open

## The Efficacy of the Proprioceptive Neuromuscular Facilitation (PNF) approach in stroke rehabilitation to improve basic activities of daily living and quality of life: a systematic review and meta-analysis protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-016739.R2
Article Type:	Protocol
Date Submitted by the Author:	18-Jul-2017
Complete List of Authors:	Guiu-Tula, Francesc; Blanquerna School of Health Science, Ramon Llull University, Physiotherapy Cabanas-Valdés, Rosa; Faculty of Medicine and Health Sciences, Universitat Internacional de Catalunya (UIC) , Physiotherapy Sitja-Rabert, Mercè; Blanquerna School of Health Science, Ramon Llull University, Physiotherapy Urrutia, Gerard; Centro Cochrane Iberoamericano; Institut d'Investigació Biomèdica Sant Pau, CIBERESP Gomara-Toldrà, Natalia; Blanquerna School of Health Science, Ramon Llull University, Physiotherapy
<b>Primary Subject Heading</b>:	Rehabilitation medicine
Secondary Subject Heading:	Neurology
Keywords:	Proprioceptive neuromuscular facilitation, PNF, Kabat, Activities of daily living, Quality of life, Stroke < NEUROLOGY

SCHOLARONE™  
Manuscripts

1  
2  
3 **The Efficacy of the Proprioceptive Neuromuscular Facilitation (PNF) approach in**  
4 **stroke rehabilitation to improve basic activities of daily living and quality of life: a**  
5 **systematic review and meta-analysis protocol**  
6  
7

8  
9 Francesc Xavier Guiu-Tula<sup>a</sup>, Rosa Cabanas-Valdés<sup>b</sup>, Mercè Sitjà-Rabert<sup>a</sup>, Gerard  
10 Urrútia<sup>c</sup>, Nàtalia Gómara-Toldrà<sup>a</sup>  
11

12  
13 <sup>a</sup>Blanquerna School of Health Science, Ramon Llull University, Physiotherapy,  
14 Barcelona, Catalonia, Spain  
15

16  
17 <sup>b</sup>Faculty of Medicine and Health Sciences, Universitat Internacional de Catalunya  
18 (UIC), Physiotherapy, Barcelona, Catalonia, Spain,  
19

20  
21 <sup>c</sup>Centro Cochrane Iberoamericano, Institut d'Investigació Biomèdica Sant Pau,  
22 CIBERESP, Barcelona, Catalonia, Spain  
23  
24

25  
26  
27  
28 Corresponding author:  
29

30  
31 [rosacabanas@uic.es](mailto:rosacabanas@uic.es) Rosa Cabanas-Valdés  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9

## The Efficacy of the Proprioceptive Neuromuscular Facilitation (PNF) approach in stroke rehabilitation to improve basic activities of daily living and quality of life: a systematic review and meta-analysis protocol

10  
11

### ABSTRACT

12  
13  
14  
15  
16  
17  
18  
19  
20  
21

**Introduction:** Proprioceptive neuromuscular facilitation (PNF) is a widely used rehabilitation concept although its efficacy has not yet been demonstrated in stroke survivors. The aim of this systematic review is to identify, assess and synthesize the potential benefits of PNF to improve the activities of daily living (ADL) and quality of life (QoL) in individuals with stroke.

22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

**Methods and analysis:** A systematic electronic search will be conducted in Medline, Embase, CENTRAL and PEDro. We will include randomized controlled trials or quasi-randomized of PNF interventions in stroke survivors until April 2017. Two reviewers authors will independently select relevant studies and will extract data using the approach of the Cochrane Handbook for systematic reviews of interventions and the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P). The methodological quality will be assessed by using the PEDro scale. Finally, the numeric data permitting, we will carry out a meta-analysis.

36  
37  
38  
39  
40  
41  
42  
43

**Ethics and dissemination:** No ethical considerations will be required. Results will be disseminated in a peer-review journal. This systematic review aims to examine the effects of PNF (neurophysiological approach) in order to clarify its efficacy to improve the ADL and QoL in the rehabilitation process of stroke survivors.

44  
45

**Trial registration number:** Prospero CRD42016039135

46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Keywords:** Stroke, Proprioceptive neuromuscular facilitation, PNF, Kabat, Activities of daily living, Quality of life, Physiotherapy.

### Strengths and limitations of this study

- To our knowledge this study is the first systematic review focused in the proprioceptive neuromuscular facilitation (PNF) approach for stroke survivors.
- This systematic review has an open eligibility criteria to clarify the efficacy of the PNF method for different clinical situations in stroke patients.
- The electronic search will only include randomized controlled and quasi-randomized controlled trials published in English, Spanish, French and Portuguese that could limit the inclusion of studies.

## INTRODUCTION

Although age-standardized rates of stroke mortality have decreased worldwide in the past two decades, the total number of people who have a stroke every year, as well as stroke survivors, related deaths, and the overall global burden of stroke (DALYs lost) is increasing.<sup>1</sup> Motor function deficits due to stroke affect the patients' mobility, their limitation in daily life activities, their participation in society and their odds of returning to professional activities. All of these factors contribute to a low overall quality of life (QoL).<sup>2</sup>

The QoL construct has evolved over the years, with multiple conceptualizations. As a result, the majority of the clinical studies do not accurately define the QoL and how it operationalized.<sup>3,4</sup> Dijkers separated QoL into three categories: (1) QoL as subjective well-being (SWB), (2) QoL as achievements, and (3) QoL as utility. QoL as SWB have been defined as the sum total of the cognitive and emotional reactions that people experience when they compare what they have and do in life with their aspirations, needs, and other expectations. QoL as achievements refers to people's possessions, relationships and accomplishments, among others, using metrics defined by an outsider's point of view. In QoL as utility, achievements and statuses are judged in terms of societal norms and standards that quantify the value of a life.<sup>4</sup> In the field of medical rehabilitation, QoL measurement commonly involved health status or was qualified by the term "health-related". Health related quality of life (HRQoL) is defined by the value assigned to duration of life as modified by impairment, functional state, perception and social factors that are influenced by the disease, injury, treatment or policy.<sup>5</sup>

Successful rehabilitation effectively addresses the components of the International Classification of Functioning (ICF) (impairment, activity limitations and participation restrictions, contextual and personal factors) with a goal of a satisfactory QoL as perceived by the individual. The relationship between the three domains of the ICF is clear: impairments have an impact on activities and activities have an impact on participation. Functionality and activities of daily living (ADL) take a specific role influencing positively QoL in stroke survivors. During the recovery process according to the disability grade, it is important to impact on that variables at any time through the rehabilitation treatment, taking into account that are variable that change over the time.<sup>6</sup> Much of the focus of stroke rehabilitation is on the recovery of impaired movement and

1  
2  
3 the associated functions. There seems to be a direct relation between motor impairment  
4 and function; for example, independence in walking (function) has been correlated with  
5 lower-limb strength (impairment).<sup>7</sup> In order to improve the neuromuscular system's  
6 effectiveness in coordinating movement and function, there are different physical  
7 rehabilitation approaches used for enhancing recovery in post stroke patients, but no one  
8 was more (or less) effective than any other approach in improving independence in  
9 ADL or motor function.<sup>8</sup> In rehabilitation practice is widely used the proprioceptive  
10 neuromuscular facilitation (PNF).<sup>9</sup>

11  
12 PNF approach has existed since the late 1930s and '40s when a physician and  
13 neurologist Herman Kabat, and a physiotherapist Margaret Knott, began using  
14 proprioceptive techniques on younger individuals with cerebral palsy and other  
15 neurological conditions. The main goal of this intervention method is to help patients to  
16 achieve their highest function level. PNF uses the body's proprioceptive system to  
17 facilitate or inhibit muscle contraction. The definition of PNF involves proprioceptive  
18 (having to do with any of the sensory receptors that give information concerning  
19 movement and position of the body); neuromuscular (involving the nerves and muscles)  
20 and facilitation (making it easier).<sup>10</sup>

21  
22 Recently, various systematic reviews have evaluated the efficacy of stroke rehabilitation  
23 interventions, including PNF<sup>11-15</sup> and a guideline.<sup>16</sup> However, none were specifically  
24 focused on PNF, with only a narrative review assessing PNF as the principal topic.<sup>9</sup>  
25 Furthermore, the most frequent objectives to assess the efficacy of this intervention  
26 method was motor function and mobility. It is necessary that therapists base their  
27 clinical decisions on the most reliable scientific evidence available; hence, this  
28 systematic review aims to determine the efficacy of PNF techniques to improve the  
29 ADL and QoL in stroke survivors, by determining the efficacy of PNF techniques.

## 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 **OBJECTIVES**

50  
51 The purpose of this systematic review is to examine the efficacy of proprioceptive  
52 neuromuscular facilitation (PNF) to improve the ADL and the QoL in individuals with  
53 stroke. Secondary specific aims are to determine the efficacy of the PNF techniques in  
54 postural control, gait, upper limb function and in muscle strength.  
55  
56  
57  
58  
59  
60

## METHODS:

This systematic review protocol was registered prospectively in Prospero (registration number: CRD42016039135) and will follow the recommendations of the Cochrane Handbook for systematic reviews of interventions<sup>17</sup> and will be reported in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P).<sup>18</sup>

### Criteria for considering studies for this review

#### *Type of studies*

We will include all randomized controlled trials and quasi-randomized controlled trials.

#### *Type of participants*

We will include adult stroke participants (>18 years old) in the acute, subacute or chronic phase.

#### *Type of interventions*

We will include all trials which reported Proprioceptive Neuromuscular Facilitation (PNF) approach alone or in combination with another rehabilitation or medical intervention compared with a control group (conventional physiotherapy, another physiotherapy approach, no PNF, no treatment).

#### *Type of outcomes measures*

Primary outcomes:

- i) Activities of daily living (ADL) evaluated mainly by Barthel Index (BI), Functional Independence Measures (FIM), modified Ranking Scale (mRS) and Community Integration Questionnaire (CIQ).
- ii) Quality of life (QoL) evaluated mainly by Medical Outcomes Study Short Form 36 (SF-36) and Stroke Specific Quality of Life Scale (SS-QOL).



1  
2  
3 Secondary outcomes:

- 4 i) Postural control assessed mainly by Postural Assessment Scale for Stroke  
5 Patients (PASS), Rivermead Mobility Index (RMI) and the Trunk  
6 Impairment Scale (TIS).  
7  
8 ii) Gait assessed mainly by Brunel Balance Assessment (BBA), Tinetti test,  
9 Functional Ambulation Category (FAC), Dynamic Gait Index (DGI), 6  
10 Minute Walk Test (6 MWT) or 10 Meter Walk Test (10 MWT).  
11  
12 iii) Upper limb function assessed mainly by Wolf Motor Function (WMFT),  
13 Fugl-Meyer Assessment (FMA), Box and Block Test (BBT) or Motor  
14 Activity Log (MAL).  
15  
16 iv) Muscle strength assessed mainly by Oxford Scale, Hand-held  
17 Dynamometer/Grip Strength or Five Times Sit to Stand Test (FTSST).  
18  
19  
20  
21  
22  
23

24 **Search methods for identification of studies**

25  
26  
27 A systematic electronic search will be conducted in the following databases: The  
28 Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library,  
29 2017, Issue 3), MEDLINE (1964 to April 2017; via PubMed), EMBASE (1980 to April  
30 2017; via Ovid) and PEDro (1999 to April 2017; via website). In addition, expert  
31 opinions' and the referent list of the selected studies and previous systematic reviews  
32 will be reviewed. The Search strategy will involve two kinds of terms: "stroke" and  
33 "PNF" that will be combined with the Cochrane Highly Sensitive Search Strategy for  
34 the identification of randomized trials in MEDLINE: sensitivity-maximizing version  
35 (2008 revision); PubMed format. Finally, all studies published in English, Spanish,  
36 French, and Portuguese will be included. This search strategy is described in table 1.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Table 1 Medline (PubMed) search strategy

	1. "Cerebrovascular Disorders"[Mesh] OR stroke*[tiab] OR poststroke*[tiab] OR cerebral vascular OR accident*[tiab] OR cva*[tiab] OR brain injur*[ti] OR apoplex*[tiab]
	2. "Brain"[Mesh] OR brain*[tiab] OR cerebr*[tiab] OR cerebell*[tiab] OR intracran*[tiab] OR intracerebral*[tiab] OR vertebrobasilar*[tiab]
	3. "Blood vessels"[Mesh] OR blood vessel*[tiab] OR vascular*[tiab] OR "arteries"[Mesh] OR arter*[tiab]
	4. "Intracranial Aneurysm"[Mesh] OR "Intracranial Hemorrhages"[Mesh] OR "Intracranial OR Hemorrhage, Hypertensive"[Mesh] OR "Hematoma, Subdural, Intracranial"[Mesh] OR "Subarachnoid Hemorrhage"[Mesh] OR "SAH"[tiab]
	5. "Hemorrhage"[Mesh] OR hemorrhag*[tiab] OR haemorrhag*[tiab] OR "hematoma"[Mesh] OR hematoma*[tiab] OR haematoma*[tiab] OR bleed*[tiab]
<b>Stroke</b>	6. "Intracranial Embolism and Thrombosis"[Mesh] OR "Intracranial Embolism"[Mesh] OR "Vasospasm, OR Intracranial"[Mesh] OR "Ischemic Attack, Transient"[Mesh] OR "TIA"[tiab] OR "Brain Ischemia"[Mesh]
	7. "Ischemia"[Mesh] OR ischemi*[tiab] OR ischaemi*[tiab] OR thrombo*[tiab] OR "embolism"[Mesh] OR emboli*[tiab] OR oclus*[tiab]
	8. "Disease"[Mesh] OR disease*[tiab] OR disorder*[tiab] OR infarc*[tiab] OR stenosi*[tiab] OR spasm*[tiab] OR accident*[tiab]
	9. (#2 AND #7) OR #6
	10. (((#2 OR subarachnoid*[tiab]) AND #5) OR #4)
	11. #17 AND #23 AND #61
	12. #1 OR #9 OR #10 OR #11
	13. Neuromuscular facilitation*[tiab] OR neuromuscular stimulation*[tiab] OR proprioceptive*[ti] OR "PNF"[tiab] OR autogenic inhibition*[tiab] OR reciprocal inhibition*[tiab] OR rhythmic stabilization*[tiab] OR repeat contraction*[tiab] OR repeated contraction*[tiab] OR hold relax*[tiab] OR antagonist contract*[tiab] OR slow reversal*[tiab] OR functional stretch reflex*[tiab] OR reflex excitability*[tiab] OR contract relax*[tiab] OR "kabat"[tiab]
<b>Proprioceptive neuromuscular facilitation (PNF)</b>	
<b>Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE: sensitivity-maximizing versión (2008 revision); PubMed format</b>	14. Randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized [tiab] OR placebo [tiab] OR drug therapy [sh] OR randomly [tiab] OR trial [tiab] OR groups [tiab]
	15. Animals [mh] NOT humans [mh]
	16. #15 NOT #16
<b>Final Search</b>	17. #12 AND #13 AND #16

## Data collection and analysis

### *Study Selection*

Two reviewers will independently screen all retrieved references and select studies that meet the inclusion criteria following these steps: (1) reading title and abstracts and then (2) by reading the full-texts.

### *Data extraction and management*

Two reviewers independently will extract data using a data extraction form, which will be designed and tested prior to use. Disparities will be resolved by discussion or if necessary, referred to a third reviewer. The data extraction form will be based on the recommendations of the Cochrane handbook for systematic reviews of interventions<sup>17</sup> and will be extracted information from each selected study on demographic characteristics (example; age, gender, time since stroke, side of the paresis, unilateral or bilateral stroke, first ever or the recurrent stroke the etiologic and the localization of stroke lesions), study design, description of intervention conducted both in the experimental and control groups, risk of bias, outcomes measures and results. For better data reporting, we will use the TIDieR (Template for intervention description and replication)<sup>19</sup> in the intervention section and the PEDro scale<sup>20</sup> to assess the risk of bias.

### *Assessment of the risk of bias in individual studies*

Two reviewers will independently evaluate the methodological quality from each selected study using the PEDro scale.<sup>20</sup> Disparities will be resolved by involving a third author.

### *Measures of treatment effect*

Within this systematic review, results from continuous outcomes will be reported with the mean difference (if the same scale is available) or standardized mean difference (if different scales were used) with 95% confidence intervals, and dichotomous outcomes with risk differences and 95% confidence intervals.<sup>17</sup>

### *Data synthesis*

If a meta-analysis is possible, statistical analysis will be conducted by Revman 5.3. We

1  
2  
3 will use a fixed effects model to summarize the results of the studies with non-  
4 significant heterogeneity; otherwise, we will use the random effects model. If there is  
5 great heterogeneity within the studies (I-squared >70%), which does not allow the  
6 performance of a meta-analysis, a narrative synthesis of the available data will be  
7 conducted.<sup>17</sup>  
8  
9

### 10 11 12 *Dealing with missing data*

13  
14  
15 If data is unreported, when possible, we will contact the original authors to request the  
16 missing data, especially for those necessary for the completion of the meta-analysis.<sup>17</sup>  
17  
18

### 19 20 21 *Assessment of heterogeneity*

22  
23 Heterogeneity will be assessed using the I<sup>2</sup> statistic according to the recommendations  
24 of the Cochrane Handbook for Systematic Reviews of Interventions<sup>17</sup> Values greater  
25 than 50% will indicate the existence of substantial heterogeneity.<sup>17</sup>  
26  
27

### 28 29 30 *Subgroup analysis and investigation of heterogeneity*

31  
32 We will consider the following variables: the etiology of the disease, type of stroke;  
33 stroke localization, stroke severity evaluated by the National institute of Health Stroke  
34 Scale (NIHSS) and modified Rankin Scale, thrombolysis and thrombectomy treatment,  
35 and the chronicity of the disease. Finally, for the evaluation of the methodological  
36 heterogeneity, will take the study design and the risk of bias of the studies included into  
37 account.<sup>17</sup>  
38  
39

### 40 41 42 *Sensitivity analysis*

43  
44 We will perform a sensitivity analysis as follows: (a) random allocation, (b) concealed  
45 allocation, (c) methodological quality, (d) subjects blinding, (e) therapists blinding, (f)  
46 outcomes assessor blinding, and (g) intention to treat analysis and (h) drop outs.<sup>17</sup>  
47  
48  
49  
50  
51

## 52 53 **DISCUSSION**

54  
55 This systematic review will focus on the different techniques of Proprioceptive  
56 Neuromuscular Facilitation (PNF) that are currently applied in stroke survivors to  
57  
58  
59  
60

1  
2  
3 explore their influence in Activities of daily living (ADL) and Quality of life (QoL).  
4 PNF has been a very important part of the therapeutic techniques for years. More  
5 recently, the focus on functional activities has allowed the techniques of PNF to become  
6 an integral part of this type of exercise programming. PNF can and should be  
7 incorporated into any functional training by stroke survivors.  
8  
9  
10

## 11 12 13 **FOOTNOTES**

14 Acknowledgements: We would like to acknowledge the contribution of Blanquerna  
15 School of Health Science (Ramon Llull University) and Iberoamerican Cochrane Center  
16 to serve their installations and services to the first author. We would like to  
17 acknowledge the contribution of Montse León (ML) and Gary Gibson (GG) for his  
18 assistance and help in the editing process of the manuscript.  
19  
20  
21  
22  
23

24 Contributor ship statement: Francesc Xavier Guiu Tula (FXGT) conceived, designed  
25 and co-ordinated the protocol review. He registered the protocol review in the Prospero  
26 database, wrote the protocol review, provided a clinical perspective and commented on  
27 drafts of the protocol review, and contributed to and approved the final manuscript of  
28 the protocol review. Rosa Cabanas Valdés (RCV) provided a clinical perspective,  
29 especially to the PNF method. She contributes to the outcome assessment and  
30 commented on drafts of the protocol review, and contributed to and approved the final  
31 manuscript of the protocol review. Mercè Sitjà-Rabert (MSR) conceived and designed  
32 the review. She provided a methodological perspective and she wrote the manuscript  
33 and commented on drafts of the protocol review, and contributed to and approved the  
34 final manuscript of the protocol review. Gerard Urrútia (GU) provided a methodological  
35 perspective, commented on drafts of the protocol review, and contributed to and  
36 approved the final manuscript of the protocol review. Natàlia Gómara Toldrà (NGT)  
37 provided a clinical perspective, especially to the assessment outcomes and quality of life  
38 construct. She wrote the manuscript and commented on drafts of the protocol review,  
39 and contributed to and approved the final manuscript of the protocol review.  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51

52 Funding: This paper will be supported by the College of Physiotherapists of Catalonia.  
53 Scholarship granted to Natàlia Gómara-Toldrà. Identification number: 43981/2015 and  
54 by the Iberoamerican Cochrane Center.  
55  
56  
57  
58  
59  
60

1  
2  
3 Competing interest: The authors declare not to have any competing interests.  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## REFERENCES

1. Feigin VL, Forouzanfar MH, Krishnamurthi R, et al. Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. *Lancet (London, England)* 2014;383:245-54.
2. Hatem SM, Saussez G, Della Faille M, et al. Rehabilitation of Motor Function after Stroke: A Multiple Systematic Review Focused on Techniques to Stimulate Upper Extremity Recovery. *Frontiers in Human Neuroscience* 2016;10:442. doi: 10.3389/fnhum.2016.00442
3. Dijkers M. "What's in a name?" The indiscriminate use of the "Quality of life" label, and the need to bring about clarity in conceptualizations. *International Journal of Nursing Studies* 2007;44:153-55. doi: 10.1016/j.ijnurstu.2006.07.016
4. Dijkers MPJM. Quality of life of individuals with spinal cord injury: a review of conceptualization, measurement, and research findings. *Journal of Rehabilitation Research and Development* 2005;42:87-110.
5. Karimi M, Brazier J. Health, Health-Related Quality of Life, and Quality of Life: What is the Difference? *Pharmacoeconomics* 2016;34:645-49. doi: 10.1007/s40273-016-0389-9
6. Carod-Artal FJ, Egido JA. Quality of life after stroke: the importance of a good recovery. *Cerebrovascular Diseases (Basel, Switzerland)* 2009;27 Suppl 1:204-14. doi: 10.1159/000200461
7. Jørgensen HS, Nakayama H, Raaschou HO, et al. Recovery of walking function in stroke patients: the Copenhagen Stroke Study. *Archives of Physical Medicine and Rehabilitation* 1995;76:27-32.
8. Pollock A, Baer G, Campbell P, et al. Physical Rehabilitation Approaches for the Recovery of Function and Mobility After Stroke: Major Update. *Stroke* 2014;45:e202-e02. doi: 10.1161/STROKEAHA.114.006275
9. Smedes F, Heidmann M, Schäfer C, et al. The proprioceptive neuromuscular facilitation-concept; the state of the evidence, a narrative review. *Physical Therapy Reviews* 2016;21:17-31. doi: 10.1080/10833196.2016.1216764
10. Adler SS, Beckers D, Buck M. PNF in Practice. Berlin, Heidelberg: Springer Berlin Heidelberg 2014.
11. Almeida PMD, Santo A, Dias B, et al. Hands-on physiotherapy interventions and stroke and International Classification of Functionality, Disability and Health outcomes: A systematic review. *European Journal of Physiotherapy* 2015;17:100-15. doi: 10.3109/21679169.2015.1044466
12. Veerbeek JM, van Wegen E, van Peppen R, et al. What is the evidence for physical therapy poststroke? A systematic review and meta-analysis. *PloS One* 2014;9:e87987. doi: 10.1371/journal.pone.0087987
13. Winter J, Hunter S, Sim J, et al. Hands-on therapy interventions for upper limb motor dysfunction following stroke. *The Cochrane Database of Systematic Reviews* 2011:CD006609. doi: 10.1002/14651858.CD006609.pub2
14. Pollock A, Baer G, Pomeroy V, et al. Physiotherapy treatment approaches for the recovery of postural control and lower limb function following stroke. *The Cochrane Database of Systematic Reviews* 2007:CD001920. doi: 10.1002/14651858.CD001920.pub2
15. Van Peppen RPS, Kwakkel G, Wood-Dauphinee S, et al. The impact of physical therapy on functional outcomes after stroke: what's the evidence? *Clinical Rehabilitation* 2004;18:833-62.

16. Ottawa P, Khadilkar A, Phillips K, et al. Ottawa panel evidence-based clinical practice guidelines for post-stroke rehabilitation. *Topics in Stroke Rehabilitation* 2006;13(2):1. doi: 10.1310/3tkx-7xec-2dtg-xqkh
17. Cochrane handbook for systematic reviews of interventions. Chichester, England ; Hoboken, NJ: Wiley-Blackwell 2011.
18. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4 doi: 10.1186/2046-4053-4-1
19. Hoffmann TC, Glasziou PP, Boutron I, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. *Bmj* 2014;348
20. Maher CG, Sherrington C, Herbert RD, et al. Reliability of the PEDro scale for rating quality of randomized controlled trials. *Physical Therapy* 2003;83(8):713.



Open-2017-016739 on 12 December 2017. Downloaded from <http://bmjopen.bmj.com/> on April 29, 2024 by guest. Protected by copyright.



# PRISMA 2009 Checklist

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

Section/topic	#	Checklist item	Reported on page #
<b>TITLE</b>			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
<b>ABSTRACT</b>			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	5
<b>METHODS</b>			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	5
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	6
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	7
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	8
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	8
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	6
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	9
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	9
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I <sup>2</sup> ) for each meta-analysis.	10



# PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	9
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	9
<b>RESULTS</b>			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	No
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	No
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	No
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	No
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measure of consistency.	No
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	No
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	No
<b>DISCUSSION</b>			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	10
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	3
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	10
<b>FUNDING</b>			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	11

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: [www.prisma-statement.org](http://www.prisma-statement.org).

Page 2 of 2

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

# BMJ Open

## The Efficacy of the Proprioceptive Neuromuscular Facilitation (PNF) approach in stroke rehabilitation to improve basic activities of daily living and quality of life: a systematic review and meta-analysis protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-016739.R3
Article Type:	Protocol
Date Submitted by the Author:	14-Aug-2017
Complete List of Authors:	Guiu-Tula, Francesc; Blanquerna School of Health Science, Ramon Llull University, Physiotherapy Cabanas-Valdés, Rosa; Faculty of Medicine and Health Sciences, Universitat Internacional de Catalunya (UIC) , Physiotherapy Sitja-Rabert, Mercè; Blanquerna School of Health Science, Ramon Llull University, Physiotherapy Urrutia, Gerard; Centro Cochrane Iberoamericano; Institut d'Investigació Biomèdica Sant Pau, CIBERESP Gomara-Toldrà, Natalia; Blanquerna School of Health Science, Ramon Llull University, Physiotherapy
<b>Primary Subject Heading</b>:	Rehabilitation medicine
Secondary Subject Heading:	Neurology
Keywords:	Proprioceptive neuromuscular facilitation, PNF, Kabat, Activities of daily living, Quality of life, Stroke < NEUROLOGY

SCHOLARONE™  
Manuscripts

1  
2  
3 **The Efficacy of the Proprioceptive Neuromuscular Facilitation (PNF) approach in**  
4 **stroke rehabilitation to improve basic activities of daily living and quality of life: a**  
5 **systematic review and meta-analysis protocol**  
6  
7

8  
9 Francesc Xavier Guiu-Tula<sup>a</sup>, Rosa Cabanas-Valdés<sup>b</sup>, Mercè Sitjà-Rabert<sup>a</sup>, Gerard  
10 Urrútia<sup>c</sup>, Nàtalia Gómara-Toldrà<sup>a</sup>  
11

12  
13 <sup>a</sup>Blanquerna School of Health Science, Ramon Llull University, Physiotherapy,  
14 Barcelona, Catalonia, Spain  
15

16  
17 <sup>b</sup>Faculty of Medicine and Health Sciences, Universitat Internacional de Catalunya  
18 (UIC), Physiotherapy, Barcelona, Catalonia, Spain,  
19

20  
21 <sup>c</sup>Centro Cochrane Iberoamericano, Institut d'Investigació Biomèdica Sant Pau,  
22 CIBERESP, Barcelona, Catalonia, Spain  
23  
24

25  
26  
27  
28 Corresponding author:  
29

30  
31 [rosacabanas@uic.es](mailto:rosacabanas@uic.es) Rosa Cabanas-Valdés  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Introduction:** Proprioceptive neuromuscular facilitation (PNF) is a widely used rehabilitation concept although its efficacy has not yet been demonstrated in stroke survivors. The aim of this systematic review is to identify, assess and synthesize the potential benefits of PNF to improve the activities of daily living (ADL) and quality of life (QoL) in individuals with stroke.

**Methods and analysis:** A systematic electronic search will be conducted in Medline, Embase, CENTRAL and PEDro. We will include randomized controlled trials or quasi-randomized of PNF interventions in stroke survivors until April 2017. Two reviewers authors will independently select relevant studies and will extract data using the approach of the Cochrane Handbook for systematic reviews of interventions and the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P). The methodological quality will be assessed by using the PEDro scale. Finally, the numeric data permitting, we will carry out a meta-analysis.

**Ethics and dissemination:** No ethical considerations will be required. Results will be disseminated in a peer-review journal. This systematic review aims to examine the effects of PNF (neurophysiological approach) in order to clarify its efficacy to improve the ADL and QoL in the rehabilitation process of stroke survivors.

**Trial registration number:** Prospero CRD42016039135

**Keywords:** Stroke, Proprioceptive neuromuscular facilitation, PNF, Kabat, Activities of daily living, Quality of life, Physiotherapy.

### Strengths and limitations of this study

- To our knowledge this study is the first systematic review focused in the proprioceptive neuromuscular facilitation (PNF) approach for stroke survivors.
- This systematic review has an open eligibility criteria to clarify the efficacy of the PNF method for different clinical situations in stroke patients.
- The electronic search will only include randomized controlled and quasi-randomized controlled trials published in English, Spanish, French and Portuguese that could limit the inclusion of studies.

## INTRODUCTION

Although age-standardized rates of stroke mortality have decreased worldwide in the past two decades, the total number of people who have a stroke every year, as well as stroke survivors, related deaths, and the overall global burden of stroke (DALYs lost) is increasing.<sup>1</sup> Motor function deficits due to stroke often affect the patients' mobility, their limitation in daily life activities, their participation in society and their odds of returning to professional activities. Motor function among others factors (as social or personal factors) could contribute to a low overall quality of life (QoL).<sup>2</sup>

A number of conceptualizations have been used through the years to describe QoL in stroke survivors.<sup>3-5</sup> The lack of an agreed definition about QoL causes that most of the QoL outcomes were assessed with standardised questionnaires. However, they do not reflect the important domains of the patients QoL and sometimes scores may be difficult to interpret.<sup>5</sup>

Dijkers<sup>4</sup> separated QoL term into three categories: (1) QoL as subjective well-being (SWB), (2) QoL as achievements, and (3) QoL as utility. QoL as SWB has been defined as the sum total of the cognitive and emotional reactions that people experience when they compare what they have and do in life with their aspirations, needs, and other expectations. QoL as achievements refers to people's possessions, relationships and accomplishments, among others, using metrics defined by an outsider's point of view. In the field of medical rehabilitation, QoL measurement commonly involved health status or was qualified by the term "health-related". Health-related QoL (HRQoL) is a major subcategory of this type of QoL: in measures developed to operationalize HRQoL, the statuses are limited very much to those traditionally under the purview of the medical establishment, including physical and mental health and symptoms. HRQoL is defined by the value assigned to duration of life as modified by impairment, functional state, perception and social factors that are influenced by the disease, injury, treatment or policy.<sup>6</sup> According to Dijkers,<sup>4</sup> some researchers, basing themselves on the World Health Organization's (WHO's) encompassing definition of health, may add to this mix social health indicators such as interactions with others and social role functioning. Finally, in QoL as utility, achievements and statuses are judged in terms of societal norms and standards that quantify the value of a life.

1  
2  
3 Successful rehabilitation effectively addresses the components of the International  
4 Classification of Functioning (ICF) (impairment, activity limitations and participation  
5 restrictions, contextual and personal factors) with a goal of a satisfactory QoL as  
6 perceived by the individual. The relationship between the three domains of the ICF is  
7 clear: impairments impact activities and activities have an impact on participation.  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Functionality and activities of daily living (ADL) take a specific role influencing positively QoL in stroke survivors. During the recovery process according to the disability grade, it is important to impact on that variables at any time through the rehabilitation treatment, taking into account that are variable that change over the time.<sup>7</sup> Much of the focus of stroke rehabilitation is on the recovery of impaired movement and the associated functions. There seems to be a direct relation between motor impairment and function; for example, independence in walking (function) has been correlated with lower-limb strength (impairment).<sup>8</sup> In order to improve the neuromuscular system's effectiveness in coordinating movement and function, there are different physical rehabilitation approaches used for enhancing recovery in post stroke patients, but no one was more (or less) effective than any other method in improving independence in ADL or motor function.<sup>9</sup> In rehabilitation practice is widely used the proprioceptive neuromuscular facilitation (PNF).<sup>10</sup>

PNF approach has existed since the late 1930s and '40s when a physician and neurologist; Herman Kabat, and a physiotherapist; Margaret Knott, began using proprioceptive techniques on younger individuals with cerebral palsy and other neurological conditions. The main goal of this intervention method is to help patients to achieve their highest function level. PNF uses the body's proprioceptive system to facilitate or inhibit muscle contraction. The definition of PNF involves proprioceptive (having to do with any of the sensory receptors that give information concerning movement and position of the body); neuromuscular (involving the nerves and muscles) and facilitation (making it easier).<sup>11</sup>

Recently, various systematic reviews have evaluated the efficacy of stroke rehabilitation interventions, including PNF<sup>12-17</sup> and a guideline.<sup>18</sup> However, none were specifically focused on PNF, with only a narrative review assessing PNF as the principal topic.<sup>10</sup> Furthermore, the most frequent objectives to assess the efficacy of this intervention method was motor function and mobility. It is necessary that therapists base their



1  
2  
3 clinical decisions on the most reliable scientific evidence available; hence this  
4 systematic review aims to determine the efficacy of PNF techniques to improve the  
5 ADL and QoL in stroke survivors, by determining the efficacy of PNF techniques.  
6  
7  
8  
9

## 10 **OBJECTIVES**

11  
12 The purpose of this systematic review is: to examine the efficacy of proprioceptive  
13 neuromuscular facilitation (PNF) to improve the ADL and the QoL in individuals with  
14 stroke. Secondary specific aims are to determine the efficacy of the PNF techniques in  
15 postural control, gait, upper limb function and in muscle strength.  
16  
17  
18  
19

## 20 **METHODS**

21  
22 This systematic review protocol was registered prospectively in Prospero (registration  
23 number: CRD42016039135) and will follow the recommendations of the Cochrane  
24 Handbook for systematic reviews of interventions<sup>19</sup> and will be reported in accordance  
25 with the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols  
26 (PRISMA-P).<sup>20</sup>  
27  
28  
29  
30  
31  
32

### 33 **Criteria for considering studies for this review**

#### 34 *Type of studies*

35  
36 We will include all randomized controlled trials and quasi-randomized controlled trials.  
37  
38  
39

#### 40 *Type of participants*

41  
42 We will include adult stroke participants (>18 years old) in the acute, subacute or  
43 chronic phase.  
44  
45  
46

#### 47 *Type of interventions*

48  
49 We will include all trials which reported Proprioceptive Neuromuscular Facilitation  
50 (PNF) approach alone or in combination with another rehabilitation or medical  
51 intervention compared with a control group (conventional physiotherapy, another  
52 physiotherapy approach, no PNF, no treatment).  
53  
54  
55  
56

#### 57 *Type of outcomes measures*

Primary outcomes:

- i) Activities of daily living (ADL) evaluated mainly by Barthel Index (BI), Functional Independence Measures (FIM), modified Ranking Scale (mRS) and Community Integration Questionnaire (CIQ).
- ii) Quality of life (QoL) evaluated mainly by Medical Outcomes Study Short Form 36 (SF-36) and Stroke Specific Quality of Life Scale (SS-QOL).

Secondary outcomes:

- i) Postural control assessed mainly by Postural Assessment Scale for Stroke Patients (PASS), Rivermead Mobility Index (RMI) and the Trunk Impairment Scale (TIS).
- ii) Gait assessed mainly by Brunel Balance Assessment (BBA), Tinetti test, Functional Ambulation Category (FAC), Dynamic Gait Index (DGI), 6 Minute Walk Test (6 MWT) or 10 Meter Walk Test (10 MWT).
- iii) Upper limb function assessed mainly by Wolf Motor Function (WMFT), Fugl-Meyer Assessment (FMA), Box and Block Test (BBT) or Motor Activity Log (MAL).
- iv) Muscle strength assessed mainly by Oxford Scale, Hand-held Dynamometer/Grip Strength or Five Times Sit to Stand Test (FTSST).

**Search methods for identification of studies**

A systematic electronic search will be conducted in the following databases: The Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, 2017, Issue 3), MEDLINE (1964 to April 2017; via PubMed), EMBASE (1980 to April 2017; via Ovid) and PEDro (1999 to April 2017; via website). In addition, expert opinions' and the referent list of the selected studies and previous systematic reviews will be reviewed. The Search strategy will involve two kinds of terms: "stroke" and "PNF" that will be combined with the Cochrane Highly Sensitive Search Strategy for the identification of randomized trials in MEDLINE: sensitivity-maximizing version (2008 revision); PubMed format. Finally, all studies published in English, Spanish, French, and Portuguese will be included. This search strategy is described in table 1.

Table 1 Medline (PubMed) search strategy

1	2. "Cerebrovascular Disorders"[Mesh] OR stroke*[tiab] OR poststroke*[tiab] OR cerebral vascular OR accident*[tiab] OR cva*[tiab] OR brain injur*[ti] OR apoplex*[tiab]
2	3. "Brain"[Mesh] OR brain*[tiab] OR cerebr*[tiab] OR cerebell*[tiab] OR intracran*[tiab] OR intracerebral*[tiab] OR vertebrobasilar*[tiab]
3	4. "Blood vessels"[Mesh] OR blood vessel*[tiab] OR vascular*[tiab] OR "arteries"[Mesh] OR arter*[tiab]
4	5. "Intracranial Aneurysm"[Mesh] OR "Intracranial Hemorrhages"[Mesh] OR "Intracranial OR Hemorrhage, Hypertensive"[Mesh] OR "Hematoma, Subdural, Intracranial"[Mesh] OR "Subarachnoid Hemorrhage"[Mesh] OR "SAH"[tiab]
5	6. "Hemorrhage"[Mesh] OR hemorrhag*[tiab] OR haemorrhag*[tiab] OR "hematoma"[Mesh] OR hematoma*[tiab] OR haematoma*[tiab] OR bleed*[tiab]
6	7. "Intracranial Embolism and Thrombosis"[Mesh] OR "Intracranial Embolism"[Mesh] OR "Vasospasm, OR Intracranial"[Mesh] OR "Ischemic Attack, Transient"[Mesh] OR "TIA"[tiab] OR "Brain Ischemia"[Mesh]
7	8. "Ischemia"[Mesh] OR ischemi*[tiab] OR ischaemi*[tiab] OR thrombo*[tiab] OR "embolism"[Mesh] OR emboli*[tiab] OR oclus*[tiab]
8	9. "Disease"[Mesh] OR disease*[tiab] OR disorder*[tiab] OR infarc*[tiab] OR stenosi*[tiab] OR spasm*[tiab] OR accident*[tiab]
9	10. (#2 AND #7) OR #6
10	11. (((#2 OR subarachnoid*[tiab]) AND #5) OR #4)
11	12. #17 AND #23 AND #61
12	13. #1 OR #9 OR #10 OR #11
13	14. Neuromuscular facilitation*[tiab] OR neuromuscular stimulation*[tiab] OR proprioceptive*[ti] OR "PNF"[tiab] OR autogenic inhibition*[tiab] OR reciprocal inhibition*[tiab] OR rhythmic stabilization*[tiab] OR repeat contraction*[tiab] OR repeated contraction*[tiab] OR hold relax*[tiab] OR antagonist contract*[tiab] OR slow reversal*[tiab] OR functional stretch reflex*[tiab] OR reflex excitability*[tiab] OR contract relax*[tiab] OR "kabat"[tiab]
14	15. Randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized [tiab] OR placebo [tiab] OR drug therapy [sh] OR randomly [tiab] OR trial [tiab] OR groups [tiab]
15	16. Animals [mh] NOT humans [mh]
16	17. #15 NOT #16
17	18. #12 AND #13 AND #16

Stroke

Proprioceptive neuromuscular facilitation (PNF)

Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE: sensitivity-maximizing version (2008 revision); PubMed format

Final Search

## Data collection and analysis

### *Study Selection*

Two reviewers will independently screen all retrieved references and select studies that meet the inclusion criteria following these steps: (1) reading title and abstracts and then (2) by reading the full-texts.

### *Data extraction and management*

Two reviewers independently will extract data using a data extraction form, which will be designed, and tested prior to use. Disparities will be resolved by discussion or, if necessary, referred to a third reviewer.

The data extraction form will be based on the recommendations of the Cochrane handbook for systematic reviews of interventions<sup>19</sup> and will extract information from each selected study on demographic characteristics (e.g. age, gender, time since stroke, side of the paresis, unilateral or bilateral stroke, first ever or the recurrent stroke the etiologic and the localization of stroke lesions), study design, description of intervention conducted both in the experimental and control groups, risk of bias, outcomes measures and results. For better data reporting, we will use the TIDieR (Template for intervention description and replication)<sup>21</sup> in the intervention section and the PEDro scale<sup>22</sup> to assess the risk of bias.

### *Assessment of the risk of bias in individual studies*

Two reviewers will independently evaluate the methodological quality from each selected study using the PEDro scale.<sup>22</sup> Disparities will be resolved by involving a third author.

### *Measures of treatment effect*

Within this systematic review, results from continuous outcomes will be reported with the mean difference (if the same scale is available) or standardized mean difference (if different scales were used) with 95% confidence intervals, and dichotomous outcomes with risk differences and 95% confidence intervals.<sup>19</sup>

### *Data synthesis*

If a meta-analysis is possible, statistical analysis will be conducted by Revman 5.3. We

1  
2  
3 will use a fixed effects model to summarize the results of the studies with non-  
4 significant heterogeneity; otherwise, we will use the random effects model. If there is  
5 great heterogeneity within the studies (I-squared >70%), which does not allow the  
6 performance of a meta-analysis, a narrative synthesis of the available data will be  
7 conducted.<sup>19</sup>  
8  
9

### 10 11 *Dealing with missing data*

12  
13 If data is unreported, when possible, we will contact the original authors to request the  
14 missing data, especially for those necessary for the completion of the meta-analysis.<sup>19</sup>  
15  
16

### 17 18 *Assessment of heterogeneity*

19  
20 Heterogeneity will be assessed using the I<sup>2</sup> statistic according to the recommendations  
21 of the Cochrane Handbook for Systematic Reviews of Interventions<sup>19</sup> Values greater  
22 than 50% will indicate the existence of substantial heterogeneity.<sup>19</sup>  
23  
24  
25  
26  
27

### 28 29 *Subgroup analysis and investigation of heterogeneity*

30  
31 We will consider the following variables: the etiology of the disease, type of stroke;  
32 stroke localization, stroke severity evaluated by the National institute of Health Stroke  
33 Scale (NIHSS) and modified Rankin Scale, thrombolysis and thrombectomy treatment,  
34 and the chronicity of the disease. Finally, the evaluation of the methodological  
35 heterogeneity, will take the study design and the risk of bias of the studies included into  
36 account.<sup>19</sup>  
37  
38  
39  
40  
41

### 42 43 *Sensitivity analysis*

44  
45 We will perform a sensitivity analysis as follows: (a) random allocation, (b) concealed  
46 allocation, (c) methodological quality, (d) subjects blinding, (e) therapists blinding, (f)  
47 outcomes assessor blinding, and (g) intention to treat analysis and (h) drop outs.<sup>19</sup>  
48  
49  
50  
51

## 52 53 **ETHICS AND DISSEMINATION**

54  
55  
56 No ethical statement will be required for this review and meta-analysis. Results of this  
57 research will be published. These results will contribute to improve the therapeutic  
58  
59  
60

1  
2  
3 strategy of patients with stroke.  
4  
5  
6  
7

## 8 DISCUSSION

9  
10 This systematic review will focus on the different techniques of Proprioceptive  
11 Neuromuscular Facilitation (PNF) that are currently applied in stroke survivors to  
12 explore their influence in Activities of daily living (ADL) and Quality of life (QoL).  
13 PNF has been a very important part of the therapeutic techniques for years. More  
14 recently, the focus on functional activities has allowed the techniques of PNF to become  
15 an integral part of this type of exercise programming. PNF can and should be  
16 incorporated into any functional training by stroke survivors.  
17  
18  
19  
20  
21  
22  
23

24  
25 Acknowledgements: We would like to acknowledge the contribution of Blanquerna  
26 School of Health Science (Ramon Llull University) and Iberoamerican Cochrane Center  
27 to serve their installations and services to the first author. We would like to  
28 acknowledge the contribution of Montse León (ML) and Gary Gibson (GG) for their  
29 assistance and help in the editing process of the manuscript.  
30  
31  
32  
33  
34

35 Authors' contributions: Francesc Xavier Guiu Tula (FXGT) conceived, designed and  
36 co-ordinated the protocol review. He registered the protocol review in the Prospero  
37 database, wrote the protocol review, provided a clinical perspective and commented on  
38 drafts of the protocol review, and contributed to and approved the final manuscript of  
39 the protocol review. Rosa Cabanas Valdés (RCV) provided a clinical perspective,  
40 especially to the PNF method. She contributes to the outcome assessment and  
41 commented on drafts of the protocol review, and contributed to and approved the final  
42 manuscript of the protocol review. Mercè Sitjà-Rabert (MSR) conceived and designed  
43 the review. She provided a methodological perspective and she wrote the manuscript  
44 and commented on drafts of the protocol review, and contributed to and approved the  
45 final manuscript of the protocol review. Gerard Urrútia (GU) provided a methodological  
46 perspective, commented on drafts of the protocol review, and contributed to and  
47 approved the final manuscript of the protocol review. Natàlia Gómara Toldrà (NGT)  
48 provided a clinical perspective, especially to the assessment outcomes and quality of life  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 construct. She wrote the manuscript and commented on drafts of the protocol review,  
4 and contributed to and approved the final manuscript of the protocol review.  
5  
6  
7

8 Funding: This paper will be supported by the College of Physiotherapists of Catalonia.  
9 Scholarship granted to Natàlia Gómara-Toldrà. Identification number: 43981/2015 and  
10 by the Iberoamerican Cochrane Center.  
11  
12

13  
14  
15 Competing interest: The authors declare not to have any competing interests.  
16  
17

18 This protocol study has been presented at the 2° Congress on NeuroRehabilitation and  
19 Neural Repair from 22 to 24 May 2017 in Maastricht, the Netharlands.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

1. Feigin VL, Forouzanfar MH, Krishnamurthi R, et al. Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. *Lancet (London, England)* 2014;383:245-54.
2. Hatem SM, Saussez G, Della Faille M, et al. Rehabilitation of Motor Function after Stroke: A Multiple Systematic Review Focused on Techniques to Stimulate Upper Extremity Recovery. *Frontiers in Human Neuroscience* 2016;10:442. doi: 10.3389/fnhum.2016.00442
3. Dijkers M. "What's in a name?" The indiscriminate use of the "Quality of life" label, and the need to bring about clarity in conceptualizations. *International Journal of Nursing Studies* 2007;44:153-55. doi: 10.1016/j.ijnurstu.2006.07.016
4. Dijkers MPJM. Quality of life of individuals with spinal cord injury: a review of conceptualization, measurement, and research findings. *Journal of Rehabilitation Research and Development* 2005;42:87-110.
5. Carr AJ, Higginson IJ. Are quality of life measures patient centred? *BMJ (Clinical research ed)* 2001;322:1357-60.
6. Karimi M, Brazier J. Health, Health-Related Quality of Life, and Quality of Life: What is the Difference? *PharmacoEconomics* 2016;34:645-49. doi: 10.1007/s40273-016-0389-9
7. Carod-Artal FJ, Egido JA. Quality of life after stroke: the importance of a good recovery. *Cerebrovascular Diseases (Basel, Switzerland)* 2009;27 Suppl 1:204-14. doi: 10.1159/000200461
8. Jørgensen HS, Nakayama H, Raaschou HO, et al. Recovery of walking function in stroke patients: the Copenhagen Stroke Study. *Archives of Physical Medicine and Rehabilitation* 1995;76:27-32.
9. Pollock A, Baer G, Campbell P, et al. Physical rehabilitation approaches for the recovery of function and mobility following stroke. *The Cochrane Database of Systematic Reviews* 2014:CD001920. doi: 10.1002/14651858.CD001920.pub3
10. Smedes F, Heidmann M, Schäfer C, et al. The proprioceptive neuromuscular facilitation-concept; the state of the evidence, a narrative review. *Physical Therapy Reviews* 2016;21:17-31. doi: 10.1080/10833196.2016.1216764
11. Adler SS, Beckers D, Buck M. PNF in Practice. Berlin, Heidelberg: Springer Berlin Heidelberg 2014.
12. Almeida PMD, Santo A, Dias B, et al. Hands-on physiotherapy interventions and stroke and International Classification of Functionality, Disability and Health outcomes: A systematic review. *European Journal of Physiotherapy* 2015;17(3):100. doi: 10.3109/21679169.2015.1044466
13. Pollock A, Baer G, Campbell P, et al. Physical rehabilitation approaches for the recovery of function and mobility following stroke. *Cochrane Database Syst Rev* 2014(4) doi: 10.1002/14651858.CD001920.pub3
14. Veerbeek JM, van Wegen E, van Peppen R, et al. What is the evidence for physical therapy poststroke? A systematic review and meta-analysis. *PloS One* 2014;9(2) doi: 10.1371/journal.pone.0087987
15. Winter J, Hunter S, Sim J, et al. Hands-on therapy interventions for upper limb motor dysfunction following stroke. *Cochrane Database Syst Rev* 2011(6) doi: 10.1002/14651858.CD006609.pub2



16. Pollock A, Baer G, Pomeroy V, et al. Physiotherapy treatment approaches for the recovery of postural control and lower limb function following stroke. *Cochrane Database Syst Rev* 2007(1) doi: 10.1002/14651858.CD001920.pub2
17. Van Peppen RP, Kwakkel G, Wood-Dauphinee S, et al. The impact of physical therapy on functional outcomes after stroke: what's the evidence? *Clin Rehabil* 2004;18(8):833-62. [published Online First: 2004/12/22]
18. Ottawa P, Khadilkar A, Phillips K, et al. Ottawa panel evidence-based clinical practice guidelines for post-stroke rehabilitation. *Topics in Stroke Rehabilitation* 2006;13(2):1. doi: 10.1310/3tkx-7xec-2dtg-xqkh
19. Cochrane handbook for systematic reviews of interventions. Chichester, England ; Hoboken, NJ: Wiley-Blackwell 2011.
20. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4 doi: 10.1186/2046-4053-4-1
21. Hoffmann TC, Glasziou PP, Boutron I, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. *Bmj* 2014;348
22. Maher CG, Sherrington C, Herbert RD, et al. Reliability of the PEDro scale for rating quality of randomized controlled trials. *Physical Therapy* 2003;83(8):713.

Open-2017-016739 on 12 December 2017. Downloaded from <http://bmjopen.bmj.com/> on April 29, 2024 by guest. Protected by copyright.



# PRISMA 2009 Checklist

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

Section/topic	#	Checklist item	Reported on page #
<b>TITLE</b>			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
<b>ABSTRACT</b>			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	5
<b>METHODS</b>			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	5
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	6
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	7
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	8
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	8
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	6
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	9
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	9
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I <sup>2</sup> ) for each meta-analysis.	10



# PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	9
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	9
<b>RESULTS</b>			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	No
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	No
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	No
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	No
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measure of consistency.	No
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	No
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	No
<b>DISCUSSION</b>			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	10
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	3
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	10
<b>FUNDING</b>			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	11

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: [www.prisma-statement.org](http://www.prisma-statement.org).

Page 2 of 2

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>